Puma Biotechnology PE ratio PBYI

Share price divided by earnings per share over the last twelve months, since 2022.

Today, Oct 23, 2026: 21.2×
4-year median: 12.3×
Against its 4-year history: 82nd; percentile: 0 is its lowest day, 100 its highest
4-year range: 3.8× to 88.9×
Peer median: 10.8×

Puma Biotechnology's PE ratio is 21.2× as of Oct 23, 2026: a share price of $11.02 against $0.52 of earnings per share over the last twelve months.

That is above its 4-year median of 12.3×, higher than on 82% of days in the last 4 years.

Over that time it ranged from 3.8× in Aug 2025 to 88.9× in Feb 2024.

The median for 10 large drugmakers of a similar size is 10.8×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	21.2×	7.8×	21.2×
2025	8.3×	3.8×	8.3×
2024	6.4×	5.0×	88.9×
2023	54.1×	18.0×	54.3×
2022	19.2×	12.3×	22.3×

Against its peers

Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.

Company	PE ratio
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
ARVNArvinas	45.6×
COLLCollegium Pharmaceutical	18.5×
ABUSArbutus Biopharma	5.4×
AMPHAmphastar Pharmaceuticals	14.8×
OMEROmeros	10.9×
PCRXPacira BioSciences	104×
ANABAnaptysbio	10.7×
Peer median	10.8×

Where Puma Biotechnology ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Puma Biotechnology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.